EGFR and non-small cell lung carcinoma: The primary aim of this study was to select several key predictors and construct a scoring system to determine whether advanced EGFR-positive NSCLC patients have a greater probability for PFS beyond one year with icotinib as EGFR-TKI targeted therapy.